Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
Farah Albader, Petra A. Golovics, Lóránt Gönczi, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 37, pp. 6231-6247
Open Access | Times Cited: 19

Showing 19 citing articles:

Decade-Long Trends in Hospitalization, Outcomes, and Emergency Department Visits for Inflammatory Bowel Diseases in the United States, 2010 to 2020
Queeneth C Edwards, Oluwatoyin Ayo-Farai, Fidelis E Uwumiro, et al.
Cureus (2025)
Open Access
Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine
Matthew B. Stanton, Mark Solinski, Stephen B. Hanauer
Expert Review of Clinical Immunology (2025), pp. 1-12
Closed Access
Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies
Akshita Bhalla, Aakash Shahi, Madhurima Maity, et al.
Cureus (2025)
Open Access
Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Krishneel Dutt, Abhinav Vasudevan
Medicina (2024) Vol. 60, Iss. 2, pp. 250-250
Open Access | Times Cited: 4
Personalized Treatment for Crohn’s Disease: Current Approaches and Future Directions
Joseph Clinton, Raymond K. Cross
Clinical and Experimental Gastroenterology (2023) Vol. Volume 16, pp. 249-276
Open Access | Times Cited: 11
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
M Kamal, Rehab H. Werida, Mahasen A. Radwan, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 3259-3269
Open Access | Times Cited: 2
Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis
Karine Rodríguez-Fernández, Javier Zarzoso-Foj, Marina Saez-Bello, et al.
Pharmaceutics (2024) Vol. 16, Iss. 10, pp. 1295-1295
Open Access | Times Cited: 2
Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study
Livia Lontai, Lóránt Gönczi, F Balogh, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 12, pp. 1639-1645
Open Access | Times Cited: 10
Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
Vlasta Oršić Frič, Vladimir Borzan, Ines Šahinović, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 239-239
Open Access | Times Cited: 4
Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing
Alina Ecaterina Jucan, Otilia Gavrilescu, Mihaela Dranga, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3090-3090
Open Access | Times Cited: 4
المراقبة الدوائية العلاجية للإنفلاكسيماب في المرضى العراقيين المصابين بمرض كرون
Hussein Hazim Saleh, Dheyaa Jabbar Khadim, Raghad Jawad Hussein
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) (2024) Vol. 6, Iss. 1, pp. 239-245
Closed Access | Times Cited: 1
Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities
Reem Al-Jabri, Panu Wetwittayakhlang, Péter L. Lakatos
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7343-7343
Open Access | Times Cited: 3
Maintenance immunosuppressive therapy for Crohn’s disease: patient adherence and its impact on treatment efficacy. Case report
A.N. Tarashchuk, M.E. Zharova, I.O. Ivanikov
Russian Journal of Evidence-Based Gastroenterology (2024) Vol. 13, Iss. 2, pp. 90-90
Closed Access
Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
Karine Rodríguez-Fernández, Javier Zarzoso-Foj, Marina Saez-Bello, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1576-1576
Open Access
Point-of-Care Assays for Infliximab Therapeutic Drug Monitoring in Patients with IBD: Is Quicker Better?
Steven Levitte
Digestive Diseases and Sciences (2023)
Open Access | Times Cited: 1
Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place
Brindusa Truta
World Journal of Gastroenterology (2022) Vol. 28, Iss. 13, pp. 1380-1383
Open Access | Times Cited: 2
Therapeutic drug monitoring for biological medications in inflammatory bowel disease
Rachel C. Cogan, Basem W. El-Matary, Wael El‐Matary
Saudi Journal of Gastroenterology (2022) Vol. 28, Iss. 5, pp. 322-331
Open Access | Times Cited: 2
Therapeutic drug monitoring in inflammatory bowel disease treatments
Mengyao Wang, Jingwen Zhao, Chang-Qing Zheng, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 15, pp. 1604-1607
Open Access | Times Cited: 1
Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment: A Pharmacokinetic Model
Rachel Levy, Manar Matar, Maya Zvuloni, et al.
Journal of Pediatric Gastroenterology and Nutrition (2023) Vol. 76, Iss. 5, pp. 576-581
Closed Access
Page 1

Scroll to top